title: Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.
abstract: Non-myeloablative regimens have been proven to allow engraftment following allogeneic stem cells transplantation (allo-SCT) with minimal procedure-related toxicity. Conventional allo-SCT may produce remissions in patients with relapsed and refractory lymphoid malignancies (LM) but these good results may be achieved at the cost of high treatment-related morbidity and mortality. Application of allo-SCT using less intensive regimens may temper the frequency of these complications, allowing a potent graft-versus-tumor effect (GVT). We present our data on 11 patients with LM receiving allo-SCT with a reduced regimen. Ten patients had received previous high-dose therapy, and were at high risk for toxicity, thus precluding the use of allo-SCT. A fludarabine and low-dose busulfan combination facilitated engraftment while exerting GVT. Hematological recovery was quick, and full donor T cell chimerism preceded acute GVHD. GVHD and infections were the major problems. Spontaneous acute GVHD occurred in eight patients (72%). Five patients (45%) achieved complete remission, and the GVT effect was closely associated with GVHD. These results support the concept that GVT is effective against LM in patients who have been heavily pretreated. Further studies are needed to investigate strategies to generate more specific alloreactive effects providing optimal GVT and an acceptable risk of GVHD and infections.
authors.affiliation: Hématologie et Oncologie Médicale, CHU de Montpellier, Montpellier, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.forename: N
authors.initials: N
authors.lastname: Fegueux
authors.forename: C
authors.initials: C
authors.lastname: Exbrayat
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Lu
authors.forename: E
authors.initials: E
authors.lastname: Legouffe
authors.forename: P
authors.initials: P
authors.lastname: Quittet
authors.forename: E
authors.initials: E
authors.lastname: Lopez-Martinez
authors.forename: P
authors.initials: P
authors.lastname: Latry
authors.forename: O
authors.initials: O
authors.lastname: Avinens
authors.forename: C
authors.initials: C
authors.lastname: Hertog
authors.forename: B
authors.initials: B
authors.lastname: Klein
authors.forename: J F
authors.initials: JF
authors.lastname: Eliaou
authors.forename: J F
authors.initials: JF
authors.lastname: Rossi
mesh_terms: D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001424:Bacterial Infections / Q000209:etiology; D005260:Female; D020350:Graft vs Tumor Effect / Q000187:drug effects* / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000401:mortality / Q000628:therapy*; D009181:Mycoses / Q000209:etiology; D015996:Survival Rate; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous; D014777:Virus Diseases / Q000209:etiology
chemical_list: D000970:Antineoplastic Agents